Up 120% in a year, ASX 200 healthcare stock dips on US acquisition

The ASX 200 healthcare company announced a strategic new US acquisition.

S&P/ASX 200 Index (ASX: XJO) healthcare stock Telix Pharmaceuticals Ltd (ASX: TLX) is slipping today.

Shares in the diagnostic and therapeutic product developer closed on Friday trading for $23.99. In morning trade on Monday, shares are changing hands for $23.76 apiece, down 0.96%.

For some context, the ASX 200 is down 1.18% at this same time.

But don't feel too bad for longer-term shareholders.

As you can see on the chart above, it's been a banner year for Telix shareholders, with the ASX 200 healthcare stock still up more than 120% over 12 months.

Here's what's happening today.

young female doctor with digital tablet looking confused.

Image source: Getty Images

ASX 200 healthcare stock expands US footprint

This morning, the ASX 200 healthcare stock announced it has entered into an asset purchase agreement with antibody engineering company ImaginAb. A concurrent technology license agreement will be signed at closing.

The purchase price for the transaction was reported to be US$45 million (AU$73 million). That's comprised of US$10 million in cash and US$31 million in equity at closing, along with a deferred payment of up to US$4 million in equity at the end of a 15-month indemnity period.

Telix said it will acquire a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility from ImaginAb to enhance its existing innovation capabilities.

The company noted this adds to its pipeline of early-stage drug candidates against high-value targets, as well as several other novel targets in discovery stage.

The transaction also includes a staffed, state-of-the-art research facility in the US state of California, providing Telix with further in-house capabilities in antibody engineering and preclinical development.

Upon achievement of specific key development and commercial milestones, the ASX 200 healthcare stock will pay up to a total of US$185 million (AU$299 million), some of which could be paid in cash or equity at Telix's discretion.

Telix will issue shares to ImaginAb as consideration for the acquisition.

What did management say?

Commenting on the strategic transaction for the ASX 200 healthcare stock, Telix Therapeutics CEO Richard Valeix said:

The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets and a talented team of subject matter experts will enhance Telix's research and innovation capability now and into the future.

This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology.

Anna M Wu, co-founder ImaginAb, added:

As the radiopharmaceutical sector gains momentum there is a significant need for targeting agents to be more selective, deliver less off-target radiation, and better match the pharmacology and radiobiology of a given radionuclide.

The team's deep expertise in antibody engineering and the resulting development of a valuable, proprietary platform technology has led to clinical proof-of-concept.

Completion of the transaction remains subject to customary conditions, including regulatory approvals and other third-party consents.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »